… and energy use. Third Quarter Fiscal 2025 Operating Results … Management Solutions (MMS) and Pharmaceutical Systems (PS) business units … This reflects strong Q3 operating performance and incremental … 2,666 INVESTING ACTIVITIES Capital expenditures (408) (429) …

… produces for global textile, pharmaceutical and consumer goods markets. … markets remained muted in the third quarter, he said. Competitive … in the quarter. No third quarter dividend was declared due … of non-essential capital expenditure resulted in a reduction …

… welcome to the Azenta Q3 2025 Financial Results. [Operator … the third quarter of fiscal year 2025. Our third quarter earnings … discontinued operations. In the third quarter, we recorded an additional … of where pharma is right now on capital expenditures. And …

… completion in the third quarter, and the Company … on planned expenditures. About Corbus Corbus Pharmaceuticals Holdings, Inc … to follow--- Corbus Pharmaceuticals Holdings, Inc. Condensed … $ (17,283 ) Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated …

… end user, the pharmaceutical and biotechnology industry sector … 𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗞𝗲𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗣𝗹𝗮𝘆𝗲𝗿𝘀 𝗔𝗿𝗲 - • Dalton Pharma Service, • Curia Global Inc, • TCG … , increase in healthcare expenditure, and the presence … report in 2021? Q3. Which is the …

Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02)/share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) --  AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent …

…     Financial Outlook “As the third quarter begins, member activity continues to … financial outlook for the third quarter and full year 2025, … our relationship with key pharmacy program partners or any … does not reflect these capital expenditures; (3) it does …

- Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - - Surpassed 50% enrollment in Phase 2 ‘START’ study of …

-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on current dataset -- -- Completed follow …

CHICAGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the second quarter ended June 30, 2025, which …